Strong Cresemba® (isavuconazole) sales in the United States trigger first sales milestone payment to Basilea
(WorldNews Switzerland)

Basel, Switzerland, October 23, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the sales of the antifungal Cresemba (isavuconazole) in the United States exceeded the threshold triggering the first sales milestone payment from Astellas Pharma Inc. (`Astellas`) to Basilea in the amount of CHF 5 million. David Veitch, Chief Commercial Officer of Basilea, said: `We are very pleased with the continued commercial success of Cresemba in the U.S. reflecting the medical need for agents treating invasive aspergillosis and invasive mucormycosis in adults and the increasing importance of Cresemba in the treatment of adults suffering from...